GenFleet's Oral Cancer Drug Enters Phase III Testing in China; Shares Up 3%

MT Newswires Live10-15

GenFleet Therapeutics (Shanghai) (HKG:2595) said Thursday its oral drug, GFH375, is now in the phase III stage of testing in China to treat a specific mutation of pancreatic cancer and non-small cell lung cancer after receiving breakthrough therapy designations for pancreatic, lung, and colorectal cancers, according to a same-day bourse filing.

Additionally, GenFleet's international partner Verastem is planning to open a registrational phase III study of the drug in combination with anti-EGFR therapy or chemotherapy, after the company's study designs met the U.S. FDA's criteria.

Shares of the company were up nearly 3% in midday trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment